JG
BBH icon

Joel Greenblatt’s VanEck Biotech ETF BBH Stock Holding History

Joel Greenblatt’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Hold
1,143
– – ﹤0.01% 1705
2026
Q1 		$215K Buy
+1,143
New +$220K ﹤0.01% 1676

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Joel Greenblatt's BBH Position: Q2 2026 in Review

Joel Greenblatt held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 1,143 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #1705.

Joel Greenblatt first reported a position in BBH in Q1 2026 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

  • Joel Greenblatt held 1,143 shares of VanEck Biotech ETF worth $232K as of Q2 2026.
  • Joel Greenblatt left its VanEck Biotech ETF share count unchanged in Q2 2026.
  • VanEck Biotech ETF made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1705 holding.
  • Joel Greenblatt first reported a position in VanEck Biotech ETF in Q1 2026 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.